drugset
drugset / Trial / NCT03766763

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

NCT03766763 ↗

Phase 2 Active not recruiting 82 enrolled French Innovative Leukemia Organisation
NaSingle-groupOpen-labelTreatment

Summary

Open label, single arm, multicenter phase II trial.

Timeline

Start
2019-05-22
Primary completion
2022-01-01
Completion
2030-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule 400 mg —

Indications

lymphoid leukemia